Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Naturally Splendid appeals Federal Court of Canada's NATERA trademark decision
09:28am, Friday, 26'th Feb 2021
Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCPINK:NSPDF) (FRA:50N), a supplier of vegetarian meat substitutes, sports and energy bars, and hemp-based products, has appealed the Federal Court of Ca
Natera: Q4 Earnings Insights
04:35pm, Thursday, 25'th Feb 2021
Shares of Natera (NASDAQ:NTRA) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 93.48% year over year to ($0.89), which missed the estimate
Why Natera (NTRA) Might Surprise This Earnings Season
09:53am, Wednesday, 24'th Feb 2021
Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Natera (NTRA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
01:42pm, Wednesday, 17'th Feb 2021
Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 Healthy Medical Stocks to Buy
11:42am, Tuesday, 09'th Feb 2021
Some medical stocks gained momentum because of the pandemic, while others focus on high-reward challenges like cancer treatment. The post 7 Healthy Medical Stocks to Buy appeared first on InvestorPlac
Natera Files Patent Infringement Suit Against Inivata
03:04pm, Wednesday, 20'th Jan 2021
SAN CARLOS, Calif., Jan. 20, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed a lawsuit today against Inivata, Ltd. and its wholly-owned su
New Data at the 2021 ASTS Winter Symposium to Showcase Benefit of Serial Prospera™ Testing
10:35am, Thursday, 14'th Jan 2021
SAN CARLOS, Calif., Jan. 14, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on the Prospera te
Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium
09:03am, Tuesday, 12'th Jan 2021
SAN CARLOS, Calif., Jan. 12, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tu
These Were the 5 Best Diagnostics Stocks of 2020
08:29am, Saturday, 09'th Jan 2021
These winners are positioned for gains even after COVID.
U.S. Patent Office Upholds Validity of Natera's Early Priority Date '592 cfDNA Patent
09:03am, Friday, 18'th Dec 2020
SAN CARLOS, Calif., Dec. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, is pleased that the United States Patent Office granted Nat
Natera: Conceive, Deliver, Thrive
05:44pm, Wednesday, 16'th Dec 2020
Increased adoption and expansion of products resulting in significant rises in volume. Producing meaningful improvements in revenues and costs per unit.
Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies
10:32am, Tuesday, 01'st Dec 2020
SAN CARLOS, Calif., Dec. 1, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United States ha
Liquid Biopsy Cancer Testing Is The Next Big Investment Opportunity
09:25am, Tuesday, 17'th Nov 2020
Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts.
SAN CARLOS, Calif., Nov. 10, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new immunotherapy data on its perso
Natera, Inc. (NTRA) CEO Steve Chapman on Q3 2020 Results - Earnings Call Transcript
12:54am, Sunday, 08'th Nov 2020
Natera, Inc. (NTRA) CEO Steve Chapman on Q3 2020 Results - Earnings Call Transcript
